Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 786.23 USD -3.15% Market Closed
Market Cap: 747.3B USD
Have any thoughts about
Eli Lilly and Co?
Write Note
Section:
 

Relative Value

The Relative Value of one LLY stock under the Base Case scenario is 301.67 USD. Compared to the current market price of 786.23 USD, Eli Lilly and Co is Overvalued by 62%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LLY Relative Value
Base Case
301.67 USD
Overvaluation 62%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

18.3
P/S
P/S
Price to Sales
18.3
vs History
14
vs Industry
8
Median 3Y
13.9
Median 5Y
9.3
Industry
2.6
Forward
16.2
More Details
89.2
P/E
P/E
Price to Earnings
89.2
vs History
22
vs Industry
2
Median 3Y
66.2
Median 5Y
46.3
Industry
23
Forward
59.1
More Details
123.8
P/OCF
P/OCF
Price to OCF
123.8
vs History
17
vs Industry
2
Median 3Y
60.8
Median 5Y
35.6
Industry
17.8
More Details
91.3
P/FCFE
P/FCFE
Price to FCFE
91.3
vs History
23
vs Industry
2
Median 3Y
76.3
Median 5Y
50.1
Industry
25.4
More Details
52.4
P/B
P/B
Price to Book Value
52.4
vs History
15
vs Industry
1
Median 3Y
35.7
Median 5Y
34.3
Industry
2.2
More Details
18.9
EV/S
EV/S
Enterprise Value to Sales
18.9
vs History
14
vs Industry
8
Median 3Y
14.4
Median 5Y
9.8
Industry
2.8
Forward
16.8
More Details
23.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
23.4
vs History
14
vs Industry
7
Median 3Y
18.6
Median 5Y
13.1
Industry
5.4
More Details
48
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
48
vs History
20
vs Industry
5
Median 3Y
45.6
Median 5Y
29.7
Industry
13.7
Forward
43.2
More Details
53.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
53.5
vs History
26
vs Industry
5
Median 3Y
54.2
Median 5Y
35.8
Industry
17.2
Forward
43.4
More Details
128
EV/OCF
EV/OCF
Enterprise Value to OCF
128
vs History
17
vs Industry
1
Median 3Y
63.2
Median 5Y
37.2
Industry
16.5
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
4
Median 3Y
49.2
Median 5Y
42.1
Industry
19.3
More Details
11.2
EV/IC
EV/IC
Enterprise Value to IC
11.2
vs History
14
vs Industry
8
Median 3Y
8.4
Median 5Y
6.7
Industry
2
More Details

Multiples Across Competitors

LLY Competitors Multiples
Eli Lilly and Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Eli Lilly and Co
NYSE:LLY
746.8B USD 18.3 89.2 48 53.5
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.4 27.8
US
Johnson & Johnson
NYSE:JNJ
365.6B USD 4.2 24.9 12 15.7
US
Merck & Co Inc
NYSE:MRK
249.1B USD 3.9 20.5 10.4 12.4
CH
Roche Holding AG
SIX:ROG
208.5B CHF 3.6 18.1 10.2 12.1
CH
Novartis AG
SIX:NOVN
181.2B CHF 4.2 12.6 10 14.8
UK
AstraZeneca PLC
LSE:AZN
159.6B GBP 4.1 31.4 168.8 253
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
US
Pfizer Inc
NYSE:PFE
147.5B USD 2.5 34.7 10.4 15.7
P/E Multiple
Earnings Growth
US
Eli Lilly and Co
NYSE:LLY
Average P/E: 33.3
89.2
451%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
24.9
-22%
US
Merck & Co Inc
NYSE:MRK
20.5
7 336%
CH
Roche Holding AG
SIX:ROG
18.1
32%
CH
Novartis AG
SIX:NOVN
12.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.4
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A
US
Pfizer Inc
NYSE:PFE
34.7
733%

See Also

Summary
LLY intrinsic value, competitors valuation, and company profile.
DCF Valuation
LLY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LLY stock valuation using valuation multiples.
Wall Street Estimates
LLY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LLY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 198,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.